Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous T-Cells with CD25 Lymphodepletion in Melanoma
NCT00945269Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2009
- Primary completion
- Jan 2011
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of therapeutic autologous lymphocytes in melanoma, sponsored by Fred Hutchinson Cancer Center. Started Jul 2009; status: terminated.
02
Drugs
therapeutic autologous lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00945269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00945269.